many patients with non-small cell lung cancer (NSCLC) derive poor benefit from immunotherapy (IO). For some of them, adding chemotherapy (CT) can improve the outcomes, but the reliability of PD-L1 expression as the only biomarker to distinguish these patients is unsatisfactory. We sought to detect clinicopathological and molecular predictive factors of survival that might be added to PD-L1 expression in the selection of patients that should receive IO alone or chemoimmunotherapy (CIT).
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis / Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea. - In: JOURNAL OF THE NATIONAL CANCER INSTITUTE. - ISSN 0027-8874. - ELETTRONICO. - 115:1(2023), pp. 29-42. [10.1093/jnci/djac205]
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis
Di Federico, Alessandro
;De Giglio, Andrea;Gelsomino, Francesco;Ardizzoni, Andrea
2023
Abstract
many patients with non-small cell lung cancer (NSCLC) derive poor benefit from immunotherapy (IO). For some of them, adding chemotherapy (CT) can improve the outcomes, but the reliability of PD-L1 expression as the only biomarker to distinguish these patients is unsatisfactory. We sought to detect clinicopathological and molecular predictive factors of survival that might be added to PD-L1 expression in the selection of patients that should receive IO alone or chemoimmunotherapy (CIT).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
